Company Interview / AFT Pharma feeling better about second half

AFT Pharmaceuticals (ASX: AFP) faces a $2.5M loss due to Asian sales disruptions. Dr Hartley Atkinson notes a doctor strike in Korea and customers destocking affecting business. Yet, strong performances in Australia and New Zealand, with sales up 19% and 14% respectively.

Hartley shares that October sales improved significantly as operations in Korea resumed and new orders sparked across international markets. Key to their growth are niche IV drugs and an expansion strategy in Europe, the UK, Canada, and the US. Pipeline projects are set to boost future revenues.

AFT's (ASX: AFP) flagship product, Maxigesic, has launched in 80 countries, with efforts underway to enter markets like Brazil and Japan. With substantial launches planned, like an antibacterial cream in China and Covid seasickness tablets in the US, AFT remains optimistic about hitting its $300M target by FY27.